Zoetis Inc. has agreed to acquire VitalRADS, a veterinary teleradiology services platform, to expand its diagnostic capabilities. The acquisition provides around-the-clock access to board-certified veterinary specialists through a cloud-based platform. This move strengthens Zoetis' position in the veterinary diagnostics market by integrating advanced teleradiology into its offerings.

The deal builds on a partnership that Zoetis announced in August 2025. By integrating VitalRADS’ capabilities, Zoetis aims to enhance its Global Diagnostics portfolio. The integration will deliver AI-assisted report generation and quality assurance, advancing the company toward a comprehensive end-to-end Virtual Reference Lab.

Strategic Benefits

The acquisition of VitalRADS is expected to bolster Zoetis' reference laboratory services. The platform's cloud-based nature allows for scalable and efficient service delivery. Key benefits include:

• 24/7 access to board-certified veterinary specialists.
• AI-assisted report generation for improved accuracy.
• Enhanced quality assurance for diagnostic outputs.

Transaction Details

Financial terms of the acquisition were not disclosed in the announcement.

Zoetis Inc. announced that the European Commission (EC) has granted marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine designed to protect chickens against Newcastle disease and Marek’s disease viruses. The authorization allows for the vaccine's use in commercial poultry operations, addressing significant mortality and production losses caused by these diseases. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both pathogens with a single dose.

Newcastle disease is classified as a notifiable disease under EU animal health regulations. Recent confirmed outbreaks in Germany, Spain, and Poland have highlighted its impact on commercial poultry. The vaccine utilizes the herpesvirus of turkey (HVT) as its vector, an avirulent virus capable of replicating in chickens that has served as a vaccine vector in poultry for approximately two decades.

Vaccine Mechanism

Poulvac Procerta HVT-ND functions by expressing a Newcastle disease virus antigen. This expression stimulates immunity against Newcastle disease while simultaneously delivering protection against Marek’s disease. The dual-action capability reduces the need for multiple vaccinations, streamlining the immunization process for poultry producers.

Key Features